Vascular Biogenics Ltd.

NasdaqCM:VBLT Stock Report

Market Cap: US$12.1m

Vascular Biogenics Balance Sheet Health

Financial Health criteria checks 6/6

Vascular Biogenics has a total shareholder equity of $19.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $24.6M and $5.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$24.26m
EquityUS$19.24m
Total liabilitiesUS$5.41m
Total assetsUS$24.65m

Recent financial health updates

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17
How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28
How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

Financial Position Analysis

Short Term Liabilities: VBLT's short term assets ($24.5M) exceed its short term liabilities ($5.3M).

Long Term Liabilities: VBLT's short term assets ($24.5M) exceed its long term liabilities ($108.0K).


Debt to Equity History and Analysis

Debt Level: VBLT is debt free.

Reducing Debt: VBLT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VBLT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VBLT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 15.7% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.